All Drug Development articles – Page 22
-
NewsRestoring the gut: VE303's strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
-
ArticlePromising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
-
NewsITM-11 boosts survival in neuroendocrine tumour trial
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
-
NewsCoherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
-
NewsFirst patient enrolled in fostamatinib trial for sickle cell disease
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
-
ArticleNew study explores safer antidepressants for pregnant women
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
-
NewsNew study shows CGM data can predict diabetes complications
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
-
ArticleFDA’s Project Optimus: A new era in oncology drug dosing
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
-
NewsCollaboration aims to advance automated insulin technology for diabetes
UVA Center for Diabetes Technology and Tandem Diabetes Care partner to advance automated insulin delivery systems for diabetes management.
-
NewsLB Pharmaceuticals announces positive schizophrenia trial data
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
-
NewsNew painless vaccine technology targets viruses
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
-
WebinarAdvancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
-
ArticleHow GPCR agonists, including antibodies, are shaping the future of metabolic care
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
-
NewsEngineers target neurons with modified lipid nanoparticles
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
-
NewsNew insights into adhesion GPCRs spark drug design potential
Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments.
-
ArticleNew research improves the safety and effectiveness of ADC cancer treatments
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
-
NewsNew data shows benefits of automated blood exchange for sickle cell disease
New studies highlight the potential of automated blood exchange to improve outcomes for sickle cell disease patients.
-
ArticleHow AI will reshape pharma in 2025
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
-
NewsNew collaboration targets key challenges in fibrosis treatment
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
-
NewsInjectable gel targets osteoarthritis pain
Hydrocelin shows promising preclinical results in treating osteoarthritis, offering pain relief and potential joint protection with no observed side effects.